JCOG (@JCOG_official) header
JCOG (@JCOG_official) profile picture

JCOG(日本臨床腫瘍研究グループ)の公式アカウントです。研究結果やイベント情報を発信します。Official account of the Japan Clinical Oncology Group (JCOG), a multicenter clinical study group founded in 1990.

Joined April 2020
Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)Photo by JCOG (@JCOG_official)
As HER2+ early breast cancer therapies keep getting better, pCR is now the rule rather than the exception. That raises a bold question: do we still need surgery? 
We'll answer it with the largest cohort reported to date. Stay tuned. @JCOG_official #SABCS26
The phase III AMATERAS-BC trial examines whether breast surgery can be omitted after a clinical complete response in early-stage HER2-positive breast cancer. Tomomi Fujisawa, MD, PhD, presents the results on December 10 at #SABCS26. bit.ly/4iXg0k3
8
2
53
4,598
JCOG group will present the results of a trial investigating the omission of surgery in patients with HER2-positive early breast cancer! #SABCS26 @JCOG_official @JGbreast Dr. Fujisawa will present the findings in GS2. Stay tuned for these exciting results!
5
1
25
5,119
ついにJCOG1806試験の結果が公表されます。@JCOG_official @JGbreast #SABCS26 のGS2、最初の発表です。藤澤先生のプレゼンテーションが今から楽しみです! 「薬物療法により臨床的完全奏効が得られたHER2陽性乳癌に対する非切除療法の有用性に関する単群検証的試験」 sabcs.org/events/
JCOG group will present the results of a trial investigating the omission of surgery in patients with HER2-positive early breast cancer! #SABCS26 @JCOG_official @JGbreast Dr. Fujisawa will present the findings in GS2. Stay tuned for these exciting results!
8
1
38
6,594
<お知らせ> 2026年11月21日(土)13:00-15:30(オンライン) #頭頸部がん 診療のシンポジウムが開催されます 主な対象:頭頸部がん診療に関わる医療関係者、研究者、メディカルスタッフ、#患者市民参画(PPI)に関心のある方 どなたでもご参加いただけます #JCOG JCOG2405試験
1
3
1
8
1,885
【研究トピックス】 上部尿路(腎盂・尿管)がん術後の膀胱内再発予防にピラルビシン膀注療法が有効であることを証明 ▼詳細はこちらよりご覧ください ncc.go.jp/jp/information/res… #上部尿路がん #腎盂尿管 #ピラルビシン #上部尿路がん #JCOG #国立がん研究センター #国立がん研究センター中央病院
3
13
2,404
【プレスリリース】 未分化型早期胃がんに対する内視鏡治療(ESD)の有効性を10年間の長期にわたる経過観察で検証 ~未分化型も内視鏡治療で胃の温存が可能~ ▼詳細はこちらよりご覧ください ncc.go.jp/jp/information/pr_… #胃がん #内視鏡治療 #ESD #国立がん研究センター #国立がん研究センター中央病院
3
26
2,024
第13回 #JCOG 患者・市民セミナー(入門編)を開催いたします 2026年8月22日(土)13:00~ jcog.jp/general/ppic/ppisemi…
1
4
1,293
【お知らせ】 JCOG乳がんグループと患者セミナー開催します。 日時:2026年8月8日(土)10:00~11:30 開催形式:Zoomによるウェビナー 参加費:無料(事前登録制) 乳癌学会でも取り上げた、JCOG臨床試験を題材に、乳がんの研究について学びます。事前質問も募集中! x.gd/vUQ9f
13
24
2,790
JCOG0802; Complex segmentectomy outcomes were good but higher risk of locoregional relapse. #ASCO26
2
3
811
🆙 #ASCO26 #LCSM Rapid Oral 🔥JCOG0802/WJOG4607L: Complex vs Simple Segmentectomy vs Lobectomy in NSCLC ✅10y OS: comp 83.5%, simp 83.5%, lobec 79.8% ✅Locoregional relapse📈comp seg (HR 2.124) 🎙️Dr. Atsushi Kamigaichi 🔢8009 🔗 asco.org/abstracts-presentat… @OncoAlert @Larvol @ASCO @IASLC
9
31
2,774
🧠📊 #ASCO26 #Sarcoma | JCOG1802 (2ND-STEP) ✔️ Trabe vs Eri vs Pazo in 2L STS (n=120) 📈 mPFS: 2.9 vs 2.2 vs 3.8 m 📈 mOS: 14.7 vs 13.3 vs 15.7 m 📈 DCR: 50% vs 37% vs 65% 🎯 Pazo: most favorable efficacy signal (NS) ⚠️ No new safety concerns; no formal between-arm comparisons @OncoAlert
13
2
17
5,952
EPISODE-III (JCOG1503C) — ASCO 2026 • Aspirin 100 mg daily for 3 years did not significantly improve DFS in unselected Stage III CRC. • HR 0.84 with a 3.4% absolute DFS difference favored aspirin, but statistical significance was not reached. • Toxicity was minimal and major bleeding was uncommon. • Ongoing biomarker analyses may clarify whether selected molecular subsets derive greater benefit. Takashima et al. #ASCO2026 #ColorectalCancer #CRC #GIOncology #MVOnco
1
5
11
1,221
Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C). No DFS benefit; PIK3KCA unknown. #ASCO2026
1
6
807
🌊AMBITION / JCOG1919E (#1019, Hara) 🧊 Can atezolizumab thaw “cold” HR+/HER2− aBC? PTX + BEV ± atezo 👥 (n=281) ❌ NEGATIVE primary endpoint: PFS 12.4 vs 11.2 mo, HR 0.88 (p=0.17) 📈 OS only numerically longer (39.1 vs 31.2 mo, HR 0.80), immature ✅ ORR high & equal (~72%) 🧊 IO still wipes out in luminal aBC. The cold stays cold. 🏄 @OncoAlert #ASCO26
2
6
708
JCOG1919E (AMBITION) #ASCO26 @9p2nNkRpjOrdvcw Adding atezolizumab to paclitaxel + bevacizumab did not significantly improve PFS in patients with HR+/HER2− advanced breast cancer (12.4 vs 11.2 months; HR 0.88; P=0.168). A numerical improvement in OS was observed (39.1 vs 31.2 months; HR 0.80; P=0.091), with a manageable safety profile consistent with known toxicities. These findings do not support the routine addition of atezolizumab to paclitaxel + bevacizumab in an unselected HR+/HER2− population.
9
2
23
8,612
📌Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial. Fumikata Hara ✨🎙️ #ASCO26 @OncoAlert #OncoAlertAF
7
10
755
#ASCO26 JCOG1919E AMBITION試験 HR陽性HER2陰性の初回抗がん剤治療としてPTX+BEV±アテゾリズマブの追加を見た医師主導治験。結果としてmPFSは12.4vs11.2カ月 PFSのHR0.876 OSもアテゾリズマブ群に良さげなトレンドはありましたが、有意差なし 両群の免疫学的背景がわかると興味深いです @9p2nNkRpjOrdvcw
1
3
20
2,301
𝗔𝗦𝗖𝗢 𝟮𝟬𝟮𝟲 | 𝗝𝗖𝗢𝗚𝟭𝟵𝟭𝟵𝗘 (𝗔𝗠𝗕𝗜𝗧𝗜𝗢𝗡) 𝗧𝗿𝗶𝗮𝗹 At #ASCO26, @9p2nNkRpjOrdvcw colleagues presented results from the phase 3 JCOG1919E (AMBITION) trial evaluating the addition of atezolizumab to paclitaxel plus bevacizumab in HR+/HER2− advanced breast cancer. 📊 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ▪️ Median PFS: 12.4 vs 11.2 months (HR 0.88) ▪️ Central review PFS: 16.7 vs 13.8 months (HR 0.92) ▪️ Median OS: 39.1 vs 31.2 months (HR 0.80) ▪️ ORR: 73.0% vs 71.9% ▪️ No new safety signals identified 🧬 Despite the biologic rationale of combining VEGF inhibition with PD-L1 blockade, the study did not meet its primary endpoint of improving PFS. 💡 These findings highlight the ongoing challenge of overcoming the immunologically "cold" biology of HR+/HER2− breast cancer, although a numerical OS improvement was observed. #ASCO2026 #AMBITIONTrial
1
4
554
🎤 #ASCO2026 🇯🇵 JCOG1919E (AMBITION) A phase III trial evaluating the addition of atezolizumab to paclitaxel (PTX) plus bevacizumab (BEV) in patients with HR-positive, HER2-negative advanced or recurrent breast cancer resistant to endocrine therapy. 📊 The study did not demonstrate an improvement in progression-free survival (PFS). Although overall survival (OS) showed a trend toward prolongation, the difference was not statistically significant. 🌍 Despite being a negative study, it was a highly anticipated trial that attracted considerable international attention and generated important discussion regarding immunotherapy strategies in HR-positive breast cancer. 👏 Congratulations to Dr. Hara on the presentation, and thank you for your tremendous efforts in leading this important study. #ASCO26 #JCOG1919E #AMBITION #BreastCancer
2
13
1,853